Failure to demonstrate high levels of serum VEGF in medullary thyroid cancer patients with distant metastases, in contrast to what happens in patients with differentiated thyroid cancer, suggests the involvement of other proangiogenic factors. The gene discussed is VEGFA; the disease is medullary thyroid gland carcinoma.